Hiwot M Tafessu
Overview
Explore the profile of Hiwot M Tafessu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shulman M, Greiner M, Tafessu H, Opara O, Ohrtman K, Potter K, et al.
JAMA Netw Open
. 2024 May;
7(5):e249744.
PMID: 38717773
Importance: Injectable extended-release (XR)-naltrexone is an effective treatment option for opioid use disorder (OUD), but the need to withdraw patients from opioid treatment prior to initiation is a barrier to...
2.
Subedi S, Nanditha N, Tafessu H, Nathani H, St-Jean M, Elefante J, et al.
BMJ Open
. 2023 Apr;
13(4):e070680.
PMID: 37076145
Objectives: Non-adherence to antipsychotics is the greatest obstacle to treating schizophrenia. We assessed the economic and clinical impacts of adherence to antipsychotics among people living with HIV/AIDS (PLWH) and schizophrenia...
3.
Greiner M, Shulman M, Opara O, Potter K, Voronca D, Tafessu H, et al.
Contemp Clin Trials
. 2023 Mar;
128:107148.
PMID: 36931426
Background: Extended-release injectable naltrexone (XR-NTX) is an effective treatment for opioid use disorder (OUD), but initiation remains a barrier to implementation. Standard practice requires a 10- to 15-day inpatient admission...
4.
Nanditha N, Dong X, Tafessu H, Wang L, Lu M, Barrios R, et al.
CMAJ Open
. 2022 Jan;
10(1):E27-E34.
PMID: 35042692
Background: In 2010, HIV treatment as prevention (TasP), encompassing widespread HIV testing and immediate initiation of free antiretroviral treatment (ART), was piloted under the Seek and Treat for Optimal Prevention...
5.
Nanditha N, Zheng G, Tafessu H, McLinden T, Bratu A, Kopec J, et al.
Can J Public Health
. 2021 Aug;
112(6):1030-1041.
PMID: 34462891
Objectives: Longer survival has increased the likelihood of antiretroviral-treated people living with HIV (PLWH) developing age-associated comorbidities. We compared the burden of multimorbidity and all-cause mortality across HIV status in...
6.
Nanditha N, Paiero A, Tafessu H, St-Jean M, McLinden T, Justice A, et al.
BMJ Open
. 2021 Jan;
11(1):e041734.
PMID: 33419911
Objectives: As people living with HIV (PLWH) live longer, morbidity and mortality from non-AIDS comorbidities have emerged as major concerns. Our objective was to compare prevalence trends and age at...
7.
Harris S, Cirino A, Carr C, Tafessu H, Parmar S, Greenberg J, et al.
Mol Genet Genomic Med
. 2019 Sep;
7(11):e940.
PMID: 31482667
Background: Individuals with hypertrophic cardiomyopathy (HCM), even when asymptomatic, are at-risk for sudden cardiac death and stroke from arrhythmias, making it imperative to identify individuals affected by this familial disorder....